KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gross Profit (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Gross Profit for 15 consecutive years, with $598.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit fell 2.02% year-over-year to $598.9 million, compared with a TTM value of $2.5 billion through Dec 2025, up 10.12%, and an annual FY2025 reading of $2.5 billion, up 10.12% over the prior year.
  • Gross Profit was $598.9 million for Q4 2025 at Biomarin Pharmaceutical, down from $636.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $675.3 million in Q2 2025 and bottomed at $305.2 million in Q3 2021.
  • Average Gross Profit over 5 years is $481.7 million, with a median of $462.8 million recorded in 2023.
  • The sharpest move saw Gross Profit fell 6.36% in 2021, then skyrocketed 30.03% in 2023.
  • Year by year, Gross Profit stood at $330.1 million in 2021, then increased by 18.43% to $390.9 million in 2022, then surged by 30.03% to $508.3 million in 2023, then rose by 20.24% to $611.2 million in 2024, then dropped by 2.02% to $598.9 million in 2025.
  • Business Quant data shows Gross Profit for BMRN at $598.9 million in Q4 2025, $636.0 million in Q3 2025, and $675.3 million in Q2 2025.